Division for Stem Cell Transplantation and Immunology, Department for Children and Adolescents, University Hospital, Goethe University, Frankfurt/Main, Germany.
Division for Pediatric Hematology and Oncology, Department for Children and Adolescents, University Hospital, Goethe University, Theodor-Stern-Kai 7, 60596, Frankfurt/Main, Germany.
Ann Hematol. 2021 Nov;100(11):2831-2841. doi: 10.1007/s00277-021-04648-z. Epub 2021 Sep 18.
Since the survival rates of pediatric patients undergoing cancer treatment or hematopoietic stem cell transplantation (HSCT) have increased rapidly in recent decades, the late effects of treatment are now an important focus of patient care. Access to fertility preservation (FP) procedures as well as their financing differs considerably across Europe. However, some countries in Europe have recently changed the legal basis for financing FP procedures; therefore, the implementation of structures is mandatory to give patients access to FP. In this prospective cohort study, we characterized the process for establishing pediatric fertility counseling, including the development of an in-house standard procedure for recommendations regarding FP with potentially gonadotoxic treatment and valuating data from all FP counseling sessions. All data concerning patient characteristics (pubertal status, disease group) and recommendation of FP measures were prospectively collected and adoption of FP measures analyzed. Prior to the establishment of a structured process for FP in our pediatric oncology and stem cell transplantation center, there was no standardized FP counseling. We demonstrate that with the establishment of an inhouse standard procedure, it is possible to give consistent yet individualized FP counseling to approximately 90% of our patients facing gonadotoxic treatment, counseling over 200 patients between 2017 and 2019. This pilot study could potentially be adapted in other pediatric hematology, oncology, and stem cell transplantation centers to allow a more standardized handling of FP counseling for all patients facing gonadotoxic treatment.
近几十年来,接受癌症治疗或造血干细胞移植 (HSCT) 的儿科患者的生存率迅速提高,因此治疗的后期影响现在是患者护理的一个重要关注点。在欧洲,获得生育力保存 (FP) 程序及其融资的途径差异很大。然而,欧洲的一些国家最近改变了 FP 程序融资的法律基础;因此,必须建立结构,使患者能够获得 FP。在这项前瞻性队列研究中,我们描述了建立儿科生育咨询的过程,包括制定内部标准程序,为潜在性腺毒性治疗提供 FP 建议,并评估所有 FP 咨询会议的数据。所有关于患者特征(青春期状态、疾病组)和 FP 措施建议的数据均前瞻性收集,并分析 FP 措施的采用情况。在我们的儿科肿瘤学和干细胞移植中心建立结构化 FP 流程之前,没有标准化的 FP 咨询。我们证明,通过建立内部标准程序,可以为面临性腺毒性治疗的大约 90%的患者提供一致但个性化的 FP 咨询,在 2017 年至 2019 年期间为 200 多名患者提供咨询。这项试点研究可以在其他儿科血液学、肿瘤学和干细胞移植中心进行调整,以便为所有面临性腺毒性治疗的患者更标准化地处理 FP 咨询。